Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
Related Articles
- CMS Relocates ESRD Survey Procedures and Interpretive Guidance Posted 06-17-2026
- CMS announced new 5-year contracts for ESRD Networks, which started May 1 Posted 06-17-2026
- Simon Davies Discusses the Role of PD in Expanding Dialysis Acess Posted 05-15-2026
- Less Home Dialysis and Transplant in Pediatric Patients Transitioning to Adult Clinics Posted 05-15-2026